
ICONICLABSPLC
CHIEFEXECUTIVEANDCHAIRMAN’SREPORT(Continued)
Page3
aggregatenominalamountof£807,754,isinadditiontoanyexistingotherauthoritiestoallotrelevant
securitiesandexpireson14June2026.
Resolution3: Disapplicationofpre‐emptionrightsinrespectofthe2019IssuanceAgreementand
theAmended2020 Issuance Agreement.This Resolution was subjectto the passing ofResolution1,
whichpassed.Inturn,thisthirdResolutionauthorisedtheCompanytodisapplythepre‐emptionrights
conferred by the Companies Act 2006 in connection with the allotment authority conferred by
Resolution1 inrespectofthe
2019IssuanceAgreementandtheAmended2020IssuanceAgreement.
This authority applies to the relevant securities which were the subject of the allotment authority
conferredbyResolution1,isinadditiontoanyexistingpowersconferredontheCompanyandexpires
on14June2026.
Resolution4: Disapplicationof
pre‐emptionrightsinrespectofanyFlexibleFacility.ThisResolution
wassubjecttothepassingofResolution2,whichpassed.Inturn,thisfourthResolutionauthorisedthe
Companytodisapplythepre‐emptionrightsconferredbytheCompaniesAct2006inconnectionwith
the allotment authority conferred by Resolution 2 in respect of any Flexible Facility. This authority
applies to the
relevant securities which are the subject of the allotment authority conferred by
Resolution2,isinadditiontoanyexistingpowersconferredontheCompanyandexpireson14June
2026.
Resolution5: Disapplicationofpre‐emptionrightsinrespectoftheallotmentauthoritiesfromthe
Company’s Annual General Meeting (“AGM”). At the Company’s AGM on 31 December 2020, the
shareholderspassedaresolutionthatauthorisedtheDirectorstoallotsharesintheCompany(andto
grantrightstosubscribefor,ortoconvertanysecurityinto,sharesintheCompany)uptoanaggregate
nominal
amountof£124,684.16aswellasuptoafurtheraggregatenominalamountof£124,684.16
in connection with a rights issue. This fifth Resolution authorised the Company to disapply the pre‐
emption rights conferred by the Companies Act 2006 in connection with the allotment authorities
conferredontheCompanyat
thelastAGMdescribedabove.Thisauthorityisinadditiontoanyexisting
powersconferredontheCompanyandexpiresattheconclusionoftheCompany’snextAGM.
E
VENTSPOSTCLOSINGOFTHE2022ACCOUNTS:
Whiletheadministrationwasstillineffectasof30June2022,withtheforegoingresolutionspassed,weturned
our attention to (i) negotiating settlements to all outstanding disputes; (ii) finalizing a CVA with the Joint
Administrators and the critical, preferential, secured, and unsecured creditors; and (iii) agreeing to financing
terms with EHGOSF to support the Company upon exiting from administration. Given the numerous parties
involved and their competing interests, complexity of the various legal and financial issues confronting the
parties,andvolumeofrelatedlegaldocumentationtobeagreedupon,thisprocesstookuntilAugust2022.
At that time, settlement
agreements resolving all disputes were finalized, and notices were issued for a
Creditors’Meetingtobeheldon22September2022toapprovetheCVAandaShareholders’GeneralMeeting
to also be held on 22 September 2022 after the Creditors’ Meeting. As part of the settlement agreements,
EHGOSFagreed
tocancelitsoutstandingconvertibleloannotesandwarrantsinexchangefornewconvertible
loannotesof £750,000,and in addition,£750,000 in newconvertible loannotes were to beissuedto Linton
Capital,whichhad beenassignedArch’sCapital’spositions.Thesenew convertibleloannotes wereissued to
EHGOSFand
LintonCapital,respectively,on19December2022,buttodatehavenotbeenconvertedintonew
sharesinIconic.
At the Creditors’ Meeting on 22 September 2022, the CVA was approved. In summary, a payment plan was
approvedoveraperiodofninemonthsforthecriticalandpreferentialcreditors
aswellasallcostsandexpenses
associatedwiththeadministration.Inaddition, unsecured creditorsagreedto be repaid inIconic shares at a
rateof£0.25per£1.00ofunsecuredclaimsagainsttheCompany,resultinginareductionofmorethan£800,000
ofliabilitiesagainstIconic.ThesenewIconic
shareswillbeissuedtotheunsecuredcreditorsonceallpayments
have been made to the critical and preferential creditors, and all costs and expense associated with the